ISPOR Europe 2019

8 november, 2019 Peter Carlqvist

Nordic Market Access presented posters this year at ISPOR…

Risk-sharing agreements for oncology drugs in Sweden – the new standard for access?

Since the end of 2014, the Dental and Pharmaceutical Benefits Agency (TLV), together with the administrative regions in Sweden, offer risk-sharing agreements (known as three-party agreements) to market authorization holders (MAH) of new innovative outpatient drugs (both in oncology and other disease areas) to be included as a part of the reimbursement conditions. On June 1, 2019, 46 reimbursed drugs were covered by a risk-sharing agreement. The first agreements for oncology drugs were made in June 2015.

Between 2014 and 2019 39% of all new oncology drugs which were reimbursed in Sweden achieved reimbursement through a risk sharing agreement. The most common uncertainties identified for risk sharing were the effect of treatment and duration of treatment.

For more information:

Market access landscape for biosimilars in Sweden, an untapped potential?

With many of the biologics facing patent expiry, the rate of introduction of biosimilars is increasing. Understanding the market access drivers and barriers of biosimilars in respect to producers of biosimilars as well as the reference products is of the outmost importance for pharmaceutical companies and for payers.

There is no national strategy for the use of biosimilars in Sweden and the uptake varies between regions. Many products have both reimbursement and participate in regional tender processes. Only one category of biosimilars (subcutaneous anti-TNF) has nationally set net prices (confidential). Market dynamics are very different for products with a retail use profile vs a hospital use profile.

For more information: